Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab in Pancreatic Adenocarcinoma
NCT04940286Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and oleclumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Major pathological response rate up to 2 years and Incidence of adverse events up to 2 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
durvalumaboleclumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04940286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940286.